- Zacks•12 days ago
Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.
- PR Newswire•13 days agoU.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Jan. 11, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, for filing through the 351(k) pathway. This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast cancers.
- Zacks•27 days ago
Mylan (MYL) and partner Biocon's biosimilar version of Herceptin phase III data published in JAMA.
BIOCON.NS : Summary for BIOCON INR5 - Yahoo Finance
Biocon Limited (BIOCON.NS)
NSE - NSE Delayed Price. Currency in INR
Add to watchlist
|Day's Range||991.10 - 1,006.80|
|52 Week Range||431.00 - 1,051.75|
|PE Ratio (TTM)||18.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|